Kailera Therapeutics, Inc. KLRA R3KPHARMA
Company Overview
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Why Investors Should Care
Generates a return on equity of 41.8%, reflecting efficient use of shareholder capital.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -36.81% |
| 6 Months: | - |
| 3 Months: | -16.60% |
| 1 Month: | -11.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)43.89 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 41.8%.
CONS
- Trading 36.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KLRA Kailera Therapeutics, Inc. R3KPHARMA | 16.43 | -7.30 | $2.13B | 0.00% | -24.52% | 41.79% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 20.46M | 84.66M |
| Operating Income | -20.46M | -84.66M |
| EBITDA | -20.39M | -84.56M |
| Interest Expense | - | - |
| Pretax Income | -17.98M | -78.86M |
| Tax Provision | - | - |
| Net Income | -17.98M | -78.86M |
| Diluted EPS | -0.15 | -0.67 |
| R&D Expense | 10.13M | 70.87M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Revenue | 0 |
| Cost of Revenue | - |
| Gross Profit | - |
| Operating Expenses | 158.34M |
| Operating Income | -158.34M |
| EBITDA | -158.03M |
| Interest Expense | - |
| Pretax Income | -148.96M |
| Tax Provision | - |
| Net Income | -148.96M |
| Diluted EPS | -1.26 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Total Assets | 178.44M | 692.29M |
| Current Assets | 177.61M | 557.54M |
| Cash & Equivalents | 175.18M | 160.27M |
| Inventory | - | - |
| Receivables | 0 | 2.73M |
| Total Liabilities | 397.22M | 1.05B |
| Current Liabilities | 6.91M | 46.41M |
| Long Term Debt | - | - |
| Total Debt | 509.00K | 10.75M |
| Total Equity | -218.77M | -356.46M |
| Shares Outstanding | 117.95M | 117.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2025 |
|---|---|
| Operating Cash Flow | -120.21M |
| Investing Cash Flow | -492.60M |
| Financing Cash Flow | 598.66M |
| Capital Expenditure | -2.09M |
| Free Cash Flow | -122.30M |
| Net Change in Cash | -14.15M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2025 |
|---|---|
| Gross Margin % | - |
| Operating Margin % | - |
| Net Margin % | - |
| ROE % | 41.8% |
| ROCE % | -24.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Bain Capital Investors Llc | 20.25% | 26.26M | $336.86M |
| 2 | Bain Capital Life Sciences Investors, LLC | 17.42% | 22.58M | $289.74M |
| 3 | RTW Investments LP | 8.31% | 10.78M | $138.27M |
| 4 | Canada Pension Plan Investment Board | 5.63% | 7.30M | $93.72M |
| 5 | Atlas Venture Life Science Advisors, LLC | 3.99% | 5.17M | $66.35M |
| 6 | FMR, LLC | 3.06% | 3.97M | $50.95M |
| 7 | Blackrock Inc. | 3.03% | 3.93M | $50.40M |
| 8 | Price (T.Rowe) Associates Inc | 2.73% | 3.53M | $45.35M |
| 9 | Citadel Advisors Llc | 2.50% | 3.24M | $41.58M |
| 10 | Adage Capital Partners GP L.L.C. | 2.47% | 3.21M | $41.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KLRA
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1pR08xOW1ZYVJwSEktQTZQRTkwMmJaS2Zqc3pMOWs1dFNOZG5KZUxwd3pQcmxycmtvSEZmSm5rNzZVWjlxd3E4UVVnT1hQX1Br?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQTkxKNGRzNXI2OGlfZVpKYUx6dlBDNXJWTjZuMlQ3RmFCZFlLZk9oc2dZSnNIZzNtR0FKWElTdDZVTTAtdC00aUpjVXRZN09fQnRTd0ZvY2l3ekVtUnlFT3doZUJpdUtRMXJ2eS1GcTlPWGVLejUtYVNRVk9OU05PdkVLZVlyb2lhXy00R2…
$KLRA stock is up 10% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQZEMySTBsclo1b1ZseFhHQUxUbW9fM2dza0N5Q2FHTEdoMmlQMnMtT01NY1BfNFROb001a0ttbkZIMnJPd1NObF9Uei16ZDJPU2RiUnozZ0VqYnIzT3kxLVJ5TWlxTmduaGRVbUtCeGJIUExxcGFtX241eGZmY0w4V292eHl6dVBhYlo4dU…
Kailera Therapeutics (KLRA) Stock Forecast and Price Target 2026 $KLRA - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5zWHRnMnhFX1BaOWF6cGh4M3VhQ0kwMEFScHFIMXlmUlozWVdxcUVoSnNuOTZSWXhKR0ZieHhreDBoUWFpUmpjNTRFRTRnSl9EVVlNYTJOOWFwM25kS3VLczU0RGxFUQ?oc=5" target="_blank">Kailera Therapeutics (KLRA) S…
Kailera Therapeutics, Inc. Common Stock (KLRA) Stock Price Today: $16.15 - Gotrade
<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTFA3clBiMkowYVhpY3ZlWVJvNlR2MmsyZVNMVzBud1pmMFhxZUZYempEZFZsSDBaVnBJbXA2QWlXUVFRdFltYU55UldsMUdTSnRfOW1TQkVMSQ?oc=5" target="_blank">Kailera Therapeutics, Inc. Common Stock (KLRA) St…
Kailera falls after late-stage trial data for oral GLP-1 candidate - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQVWFDRDVaanVjSDFGazR3c2lmTzhJdC1JMW5uNHBVTVlPeVRkeWFXZ1FkdEJTT3h0VEtrTFB2ZGZvQlVoUWFKNEtoOERUMkZhLUl6V3VndFlrSnd2MnJUZzNCVnlRNUFWOUxCWm5qSmNiTGRpZk1ybVo1b3pQSk80Nlo4UTJJeThmTEhWUE…
KLRA — Frequently Asked Questions
What is the current share price of Kailera Therapeutics, Inc. (KLRA)?
As of 2026-09-19 21:16 PDT, Kailera Therapeutics, Inc. (KLRA) trades at $16.43 on NasdaqGS. Its 52-week range is $15.40 to $26.00.
What is the market capitalisation of KLRA?
Kailera Therapeutics, Inc. (KLRA) has a market capitalisation of $2.13B on NasdaqGS.
What is the P/E ratio of KLRA?
KLRA trades at a trailing price-to-earnings (P/E) ratio of -7.30. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.49.
What is the return on equity (ROE) of KLRA?
KLRA has a return on equity (ROE) of 41.79%. Its return on capital employed (ROCE) is -24.52%.
Is KLRA a good stock to buy?
This page provides a data-driven analysis of Kailera Therapeutics, Inc. (KLRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.